News and Events
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
SAN DIEGO – March 21, 2019 – Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in Atlanta, Georgia, March 29 to April 4, 2019. The data from multiple studies and indications demonstrate the feasibility of Epic’s Functional Cell Profiling (FCP) technology to predict patients’ response to cancer immunotherapies and drugs that target DNA damage repair pathways.
Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State
SAN DIEGO, Calif., March 20, 2019 -- Epic Sciences, Inc. (Epic) announced today that the New York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer (mCRPC). The Oncotype DX AR-V7 Nucleus Detect test helps determine which patients may benefit from androgen receptor signaling inhibitor (ARSi) therapy and which may benefit from chemotherapy. The Oncotype DX AR-V7 Nucleus Detect test is a circulating tumor cell (CTC)-based, liquid biopsy test that is commercially available in the United States through Epic's partnership with Genomic Health.
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
New data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.
Epic Sciences to Present Data at SABCS 2018
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.
Calendar of Events
American Association for Cancer Research Annual Meeting in Atlanta, GA from March 29 - April 3, 2019.
ASCO GU 2019
ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.
In the News
Epic Sciences Nabs NY State Approval for AR-V7 Prostate Cancer Test
NEW YORK (360Dx) – Epic Sciences said today that its lab is now licensed by the New York State Department of Health to provide its Oncotype DX AR-V7 Nucleus Detect test for residents with metastatic castration-resistant prostate cancer.
AR-V7 status predicts abiraterone, enzalutamide response in mCRPC
The PROPHECY study represents a multicenter effort that provides prospective, blinded clinical validation around such an approach and suggests that both the JHU CTC AR-V7 mRNA assay and the Epic CTC nuclear-specific AR-V7 protein assay provide clinical utility around the anticipated outcomes with therapy.
Test Predicts Resistance to Hormonal Therapy in Prostate Cancer - Validation study confirms assist in decision-making
A blood test that measures the spliced variant of an androgen receptor called AR-V7 in circulating tumor cells successfully predicted resistance to commonly used hormonal therapy agents in advanced prostate cancer, a validation study confirmed.
Blood Tests Predict Effectiveness of Hormonal Therapies
A multi-institutional group of clinical researchers, led by the Duke Cancer Institute’s Andrew Armstrong, MD, McS, FACP, published a new report this month in the Journal of Clinical Oncology, that describes results from the PROPHECY study, which prospectively compared two blood tests to assess how well they predicted the effectiveness of hormonal therapy in men with metastatic prostate cancer.
Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target
Epic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone therapy.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.